Risedronate treatment and extended fracture protection in postmenopausal women.
Harris
S T
ST
D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005260:Female; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012219:Rheumatology / Q000379:methods*; D000068296:Risedronic Acid; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D002121:Calcium Channel Blockers; D000068296:Risedronic Acid; D012968:Etidronic Acid